Allegria Therapeutics funding news – Biotech Startup Allegria Therapeutics Secures USD3.5M in Seed Funding

Furthermore, the company announced the appointment of co-founder Maria van Dongen, PhD as Chief Executive Officer. Dr. van Dongen brings broad industry experience with a strong track record in Pharma. She previously held positions at amongst others Johnson & Johnson, where she facilitated external partnerships aiming at e.g., the effective targeting of RNA processing and the discovery of peptide-based therapeutics.

Previously, she led numerous R&D projects that included the discovery of highly innovative orally active broad-spectrum influenza antivirals, and an R&D platform dedicated to pharmaceutical interventions for disease prevention.

Read also - [Funding News ] Real Estate Data Management Platform Stonal Secures up to €100 Million in Funding

ALLEGRIA's R&D activities focus on mast cells as mediators of allergy and inflammatory diseases, a class of indications that constitutes an increasing burden world-wide.More and more patients suffer from the impact that these conditions have on their quality of life.

With the current financing, ALLEGRIA will progress a differentiated portfolio of proprietary therapeutic approaches around targets that selectively modulate mast cells to more effectively address patients' needs.

ALLEGRIA collaborates with world leading partners in fundamental mast cell biology, drug discovery and preclinical drug evaluation including Prof. Marcus Maurer, Managing Director of the Institute for Allergy Research at Berlin's Charité and Dr. Philipp Starkl, Principal Investigator at the Medical University of Vienna.

About Allegria Therapeutics

Allegria Therapeutics was founded in Basel, Switzerland by Forty51 Ventures in 2023. Pursuing a differentiated portfolio of proprietary therapeutic approaches around biological targets that selectively modulate mast cells, Allegria plans to redefine the treatment landscape for allergy and mast cell-mediated inflammatory diseases.